Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

被引：0
|
作者：
François Laliberté
Michel Cloutier
Concetta Crivera
Winnie W. Nelson
William H. Olson
Jeffrey Schein
Julie Vanderpoel
Guillaume Germain
Patrick Lefebvre
机构：
[1] Groupe d’analyse,
[2] Ltée,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Anticoagulant agents; Atrial fibrillation; Cost; Rivaroxaban; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：216 / 227
页数：11
相关论文
共 50 条
  • [31] Warfarin versus rivaroxaban in long term acute care patients with nonvalvular atrial fibrillation: a budget impact analysis
    Bell, Brian
    Frantz, Kyle
    Jones, Brayton
    Zeitlin, Deborah
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (03) : 414 - 414
  • [32] Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
    Sood, Nitesh
    Ashton, Veronica
    Bessada, Youssef
    Galli, Katelyn
    Bookhart, Brahim K.
    Coleman, Craig I.
    TH OPEN, 2023, 07 (01) : e82 - e93
  • [33] Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Sherwood, Matthew W.
    Douketis, James D.
    Patel, Manesh R.
    Piccini, Jonathan P.
    Hellkamp, Anne S.
    Lokhnygina, Yuliya
    Spyropoulos, Alex C.
    Hankey, Graeme J.
    Singer, Daniel E.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    Califf, Robert M.
    Becker, Richard C.
    CIRCULATION, 2014, 129 (18) : 1850 - 1859
  • [34] The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
    Koroleva, Lyubov Yu.
    Kolesnichenko, Irina V.
    Nosov, Vladimir P.
    Zlobin, Maxim V.
    Abelevich, Dmitry I.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (05) : 553 - 557
  • [35] Major bleeding among rivaroxaban users with nonvalvular atrial fibrillation and heart failure
    Peacock, W. F.
    Tamayo, S. Sally
    Yuan, Z.
    Sicignano, N. M.
    Hopf, K.
    Patel, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 62 - 63
  • [36] Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease
    Coleman, C. I.
    Sood, N.
    Bunz, T. J.
    Eriksson, D.
    Meinecke, A. -K.
    Baker, W. J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2982 - 2982
  • [37] Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
    Costa, Olivia S.
    Beyer-Westendorf, Jan
    Ashton, Veronica
    Milentijevic, Dejan
    Moore, Kenneth Todd
    Bunz, Thomas J.
    Coleman, Craig, I
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (07) : 1081 - 1088
  • [38] IMPACT OF RENAL FUNCTION ON CLINICAL OUTCOMES AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH WARFARIN OR RIVAROXABAN
    Weir, M. R.
    Haskell, L.
    Berger, J. S.
    Ashton, V
    Laliberte, F.
    Crivera, C.
    Brown, K.
    Lefebvre, P.
    Schein, J. R.
    VALUE IN HEALTH, 2017, 20 (05) : A261 - A262
  • [39] Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
    Pink, J.
    Pirmohamed, M.
    Hughes, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 269 - 276
  • [40] Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation
    Deitelzweig, Steven
    Luo, Xuemei
    Gupta, Kiran
    Trocio, Jeffrey
    Mardekian, Jack
    Curtice, Tammy
    Lingohr-Smith, Melissa
    Menges, Brandy
    Lin, Jay
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (11): : 1191 - 1201
12345